Sutro Biopharma Inc.
This article was originally published in Start Up
Scientists have long tinkered with cell-free methods of protein synthesis, but turning their lab bench discoveries into commercially actionable ones is usually a tedious affair that ultimately requires the return to traditional cell line development. Sutro Biopharma claims to have developed a speedy cell-free way of producing proteins that can swiftly shift from laboratory to commercial scale. Rather than packaging the process for widespread use by researchers, Sutro is seeking to collaborate with partners intent on creating biopharmaceuticals--ideally, companies interested in high-throughput protein engineering.
You may also be interested in...
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Start-Ups Set Sights on Flu," features profiles of Alios BioPharma, Immune Targeting Systems, Marinomed Biotechnologie and Vivaldi Biosciences. Plus these Start-Ups Across Health Care: CardiAQ Valve Technologies, NKT THerapeutics, SPOC Inc.,and Sutro Biopharma.
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.